Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nexagon in Persistent Corneal Epithelial Defects From Chemical Burns
NCT00821561Phase 2Withdrawn
- Sponsor
- OcuNexus Therapeutics
- Start
- Mar 2009
- Primary completion
- Nov 2009
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
01
Overview
A Phase 2 trial of lufepirsen in persistent corneal epithelial defect (PED), sponsored by OcuNexus Therapeutics. Planned start Mar 2009; status: withdrawn.
02
Drugs
lufepirsen
03
Conditions
persistent corneal epithelial defect (PED)
Beyond the preview
Go deeper on NCT00821561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00821561.